Hjem › Nyrekreft › Tennessee › Nashville
Kliniske studier for Nyrekreft i Nashville, TN
12 studier for Nyrekreft søker deltakere på steder i og rundt Nashville (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RekruttererFase 1
- Research Site, Nashville
- Research Site, Nashville
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
RekruttererFase 1
- Sarah Cannon Research Institute (SCRI), Nashville
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
RekruttererFase 3
- Research Site, Nashville
- Research Site, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekruttererObservasjonsstudie
- Vanderbilt University Medical Center, Nashville
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RekruttererFase 1/2
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC- Elliston Place Plaza, Nashville
- og 11 flere
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RekruttererFase 1
- SCRI Oncology Partners, Nashville
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RekruttererFase 1
- Xencor Investigative Site, Nashville
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RekruttererFase 1
- SCRI - Oncology Partners, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Sarah Cannon Research Institute, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Rekrutterer
- Vanderbilt-Ingram Cancer Center, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Nashville
Nyrekreft-studier i andre byer
- New York City, NY15 studier
- Boston, MA12 studier
- Houston, TX10 studier
- San Diego, CA9 studier
- St. Louis, MO9 studier
- Dallas, TX9 studier
- Washington, DC9 studier
- Seattle, WA8 studier
- Edison, NJ8 studier
- Miami, FL8 studier
- Los Angeles, CA7 studier
- Rochester, MN7 studier
Andre studier i Nashville
- Ikke-småcellet lungekreft97 studier
- Brystkreft81 studier
- Metastatisk kreft70 studier
- Kolorektal kreft69 studier
- Kreft (alle typer)65 studier
- Eggstokkreft49 studier
- Prostatakreft43 studier
- Lungekreft40 studier
- Plateepitelcancer i hode og hals39 studier
- Pankreaskreft39 studier
- Endometriekreft38 studier
- Melanom33 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.